Silence Therapeutics: Divesiran Targets High-Burden PV

Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...
The American Journal of Managed Care

Managing Polycythemia Vera to Reduce Risks and Improve Lives

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. In this interview, Andrew Kuykendall, MD, ...
Yahoo Finance

Polycythemia Vera Market Insight, Epidemiology and Market Forecast, 2034: JAKAFI & BESREMi Lead Polycythemia Vera Market, But New Therapies Poised to Disrupt by 2034

Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "Polycythemia Vera - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report ...
Healio

Rusfertide reduces hematocrit without phlebotomy in polycythemia vera

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...
The Globe and Mail

Polycythemia Vera Market Expands as FDA Fast Tracks New Treatments and Clinical Trials Show Promising Results | DelveInsight

The 7MM Polycythemia Vera market size reached approximately USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP ...

Dr. Roach: Symptoms, not numbers, are the main drivers for a phlebotomy

Dear Dr. Roach: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was ...
techtimes

New Drug Rusfertide Shows Promise in Treating Polycythemia Vera, Revealing Positive Outcomes

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...
Cure Today

Givinostat Demonstrates Long-Term Clinical Benefit in Polycythemia Vera

At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects. Patients with polycythemia vera ...
Medscape

Aspirin effective for polycythemia vera

Rome, Italy - A new double-blind, placebo-controlled study has shown that low-dose aspirin can prevent thrombotic complications in patients with polycythemia vera, provided they have no ...
Mena FN

Polycythemia Vera Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

DelveInsight's, “Polycythemia Vera Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycythemia Vera pipeline landscape. It covers the ...
Healthline

How to Know if Your Polycythemia Vera Treatment Is Working

Polycythemia vera (PV) is a rare blood cancer causing the bone marrow to make too many blood cells. Treatment usually starts with phlebotomy and may continue with medications. If one treatment isn’t ...
The Vindicator

Symptoms are main drivers for a phlebotomy

My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his HCT was high. My ...